HOME - The Journal of Precision Medicine

LATEST NEWS

Blueprint Medicines Reports Second Quarter 2022 Results

adminpmls20162022-08-10T21:02:03-05:00August 10th, 2022|

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

adminpmls20162022-08-10T20:54:23-05:00August 10th, 2022|

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

adminpmls20162022-08-10T20:50:25-05:00August 10th, 2022|

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

adminpmls20162022-08-10T20:46:27-05:00August 10th, 2022|

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

adminpmls20162022-08-10T20:42:15-05:00August 10th, 2022|

Myocardial Infarction Features Found With Multiomic Molecular Map

adminpmls20162022-08-10T20:39:10-05:00August 10th, 2022|

Beyond 1M Genomes Project Releases Recommendations to Guide European Genomic Data Initiative

adminpmls20162022-08-10T20:34:45-05:00August 10th, 2022|

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

adminpmls20162022-08-10T20:31:51-05:00August 10th, 2022|

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

adminpmls20162022-08-10T20:27:43-05:00August 10th, 2022|

Join Us in Chicago next week at the Precision Oncology and Diagnostics event! Register Now with code VIP for only $99!
2 months ago
Blueprint Medicines Reports Second Quarter 2022 Results - thejournalofprecisionmedicine.com/blueprint-medi…
4 months ago
GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution - thejournalofprecisionmedicine.com/genomoncology-…
4 months ago

LATEST ISSUE

The Journal of Precision Medicine - September 2022

Why Equitable Access in the Treatment of Cancer Depends on Comprehensive Genomic Profiling

Clinical Implications and Utility of Polygenic Risk Scores in Women at Elevated Risk for Breast Cancer

The Almac Clinical Technologies Team on Clinical Trial Design and Execution with their Clients

Integrating Personalized Medicine into Preventive Care through Risk Stratification

Access to Comprehensive Genomic Profiling (ACGP) Coalition

Twenty years of RNA research and diagnostic development… What have we learnt?

Genomic Innovation Democratizes Precision Medicine

The Rise of Predictive Genomics

Prospective Clinicogenomic Program (PCG) at Flatiron

Bringing complexity into clarity with Qlucore Diagnostics: Clinical use of transcriptomic data to classify cancer patients

Clinical Performance and Value Vignettes (CPVs) Decrease Clinical Care Variation, Improve Patient Outcomes, and Decrease Costs

ARCHIVE ISSUES

June 2022

Articles include:
The Center for Applied Genomics at The Children’s Hospital of Philadelphia: Perspectives on a Decade with the Electronic Medical Records and Genomics (eMERGE) Consortium, Clinical trials for the management of malignant lymphoma and leukemia.

Read More

March 2022

Articles include:
Applications of Spatial‑Omics in Clinical Translational Cancer Research, Illumina‑SomaLogic Deal to bring together genomics and proteomics technology platforms, How I Learned the Hard Way to Ask Questions About Medications.

Read More

September 2021

Articles include:
The Integration of Personalized Medicine into Healthcare: Advancing the Promise to More Patients, The value of adding RNA sequencing to precision biomarker strategy, As Targeted Therapies Expand Beyond Cancer, Companion Diagnostics Must Improve.

Read More

June 2021

Articles include:
myRabble: A novel patient platform to improve access to personalized medicine, Clinical data and precision medicine: The urgent need for in‑house NGS capabilities at community hospitals.

Read More

LATEST NEWS

Blueprint Medicines Reports Second Quarter 2022 Results

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

Myocardial Infarction Features Found With Multiomic Molecular Map

Beyond 1M Genomes Project Releases Recommendations to Guide European Genomic Data Initiative

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

Recent Tweets

LATEST ISSUE

ARCHIVE ISSUES

June 2022

March 2022

September 2021

June 2021

SUBSCRIBE